Notice and Orders - Multicounty Litigation - Designation of Litigation Involving GLP-1 Products Alleging (1) Gastrointestinal Injuries and (2) NAION Vision Loss Injuries as Two Separate MCLs

A previous Notice to the Bar requested comments on two applications for multicounty litigation (MCL) designation of New Jersey state-court litigation alleging injuries caused by GLP-1 medications (Ozempic®, Wegovy®, Rybelsus®, Trulicity®, Mounjaro®, and Zepbound®). The applications requested that GLP-1 litigation involving (1) gastrointestinal injuries and (2) Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) vision loss be designated as separate and distinct MCLs. This Notice is to advise that the Supreme Court, after considering the two applications and the comments received, has determined to designate the two types of cases as separate and distinct multicounty litigations. The Court has assigned both MCLs to Bergen County for centralized case management by Superior Court Judge Gregg A. Padovano.

Published with this Notice are the two October 16, 2025 Supreme Court Orders. The Orders will be posted in the Multicounty Litigation Center https://www.njcourts.gov/attorneys/multicounty-litigation on the Judiciary’s website (www.njcourts.gov). Judge Padovano’s Initial Case Management Orders also will be posted in the Multicounty Litigation Center.

Questions concerning this matter may be directed to Melissa A. Czartoryski, Chief, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P. O. Box 981, Trenton, New Jersey 08625-0981; telephone: (609) 815-2900 ext. 54901; e-mail address: Melissa.Czartoryski@njcourts.gov.